Guselkumab is a medicine used to treat psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease. It is given as an injection under the skin, and sometimes through an IV drip at the start of treatment for bowel disease. It works by blocking a signal in the immune system that drives swelling and skin plaques.
Every report comes from a Lived member, sent anonymously.
Have you tried Tremfya (Guselkumab) for Psoriasis?
Guselkumab, sold as Tremfya, is a prescription biologic medicine that calms a specific part of the immune system involved in several long-term inflammatory diseases. In the US it is approved for moderate to severe plaque psoriasis in people who need treatment beyond creams (pills, injections or light therapy), and for active psoriatic arthritis, the joint inflammation that can accompany psoriasis. For both, it can be used by adults and by children 6 and older who weigh at least 40 kg (about 88 pounds). It is also approved for adults with moderately to severely active ulcerative colitis and Crohn's disease, the two main forms of inflammatory bowel disease. A biologic like this is usually considered when the disease is significant enough to affect daily life, or when other treatments have not worked well enough.
Guselkumab is a monoclonal antibody, a lab-made protein designed to recognize one specific target. Its target is interleukin-23 (IL-23), a signaling protein the immune system uses to sustain certain kinds of inflammation. In psoriasis, psoriatic arthritis and inflammatory bowel disease, IL-23 helps keep a cycle of inflammation running in the skin, joints or gut. Guselkumab attaches to IL-23 and stops it from activating its receptor, which reduces the release of other inflammatory messengers further down the chain. The result is less inflammation in the affected tissue, which over weeks can mean thinner, less red plaques, less joint swelling or calmer bowel symptoms.
Tremfya is given as an injection under the skin using a prefilled pen, a One-Press injector or a prefilled syringe. For psoriasis and psoriatic arthritis, the usual schedule is one 100 mg injection at the start, another four weeks later, and then one every eight weeks. For psoriatic arthritis it can be used alone or alongside methotrexate. Ulcerative colitis and Crohn's disease start with a stronger induction phase: three doses at weeks 0, 4 and 8, given either as an intravenous (IV) infusion over at least an hour in a clinic or as two 200 mg injections under the skin each time. Maintenance injections follow, either every eight weeks or every four weeks depending on the dose the specialist chooses. Adults can learn to inject themselves, and the first self-injection is done with a health professional's guidance. Children should not inject themselves; a trained caregiver or clinician gives the dose. Letting the pen or syringe sit out of the refrigerator for about 30 minutes before injecting makes it more comfortable, and injections should go into clear skin rather than areas that are bruised, tender or covered by psoriasis. If a dose is missed, take it as soon as you remember and then return to the regular schedule.
Many people notice few side effects. The most common are colds and other upper respiratory infections, headache, and redness, bruising or soreness where the injection was given. Joint pain, diarrhea, stomach bugs, tiredness, fungal skin infections such as athlete's foot and cold sores also occur somewhat more often than with a placebo. People treated for Crohn's disease or ulcerative colitis may also notice fever, rash or abdominal pain. Serious allergic reactions, including anaphylaxis, have been reported. Stop using Tremfya and get emergency help right away for fainting or lightheadedness, swelling of the face, lips, tongue or throat, or trouble breathing or chest tightness.
Because guselkumab dampens part of the immune response, it can make infections more likely. It is not started while someone has a significant active infection. Contact the care team right away about fever, sweats or chills, a cough or shortness of breath, warm, red or painful skin, or burning when urinating, since treatment may need to pause until an infection clears. Everyone is tested for tuberculosis (TB) before starting, and a hidden (latent) TB infection is treated first. A new unexplained fever, persistent cough or breathing difficulty during or after treatment should be reported, as it can signal TB. Liver injury has been reported, so people treated for ulcerative colitis or Crohn's disease have liver blood tests before starting and regularly through at least the first 16 weeks; for psoriasis these tests are done when the prescriber thinks they are needed. Yellowing of the skin or eyes, dark urine, or unexplained nausea, vomiting, stomach pain, rash or loss of appetite need prompt medical attention the same day. Avoid live vaccines (vaccines made from weakened live germs) during treatment, and catch up on recommended vaccines before starting. Share a complete list of medicines and supplements with the prescriber; for a few drugs where small changes in blood levels matter, extra monitoring may be considered when Tremfya begins. There is not enough information to know whether guselkumab affects pregnancy, though antibodies like it cross the placenta, mostly late in pregnancy, so an exposed newborn may carry some of the medicine. Anyone pregnant, planning pregnancy or breastfeeding should weigh this with their care team, keeping in mind that uncontrolled bowel disease itself raises pregnancy risks.
Improvement builds over the first few months rather than overnight. In the main psoriasis trials, about 7 in 10 adults had skin that was at least 90 percent clearer after 16 weeks, and about 8 in 10 were rated clear or almost clear, compared with very few on a placebo. Joint and bowel symptoms are assessed on a similar timescale, and the specialist will judge after the first months whether the response is good enough to continue. Guselkumab controls these diseases rather than curing them. In one study, people whose psoriasis had cleared and who kept taking it were far more likely to stay clear at nearly a year (89 percent) than those who stopped (37 percent), so it is usually a long-term treatment. Ongoing care includes periodic visits, any scheduled liver tests, staying alert to infections, and keeping vaccines up to date.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tremfya (Guselkumab), what you've noticed, or ask the community a question.